ArticleMedComm2024
Magnetic resonance imaging-based radiomics analysis for prediction of treatment response to neoadjuvant chemoradiotherapy and clinical outcome in patients with locally advanced rectal cancer: A large multicentric and validated study.
Article in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomic Analysis of MRI for Assessing Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma: A Systematic Review and Metaanalysis.Molecular imagingPooled it
- Review
- CT-derived extracellular volume fraction and AI-assisted body composition for predicting neoadjuvant therapy response and prognosis in colorectal cancer.Abdominal radiology (New York) · 2026Article
- Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.Molecular oncology · 2026Article
- MRI Habitat Analysis for Preoperative Prediction of Perineural Invasion and Prognostic Stratification in Rectal Cancer.Journal of magnetic resonance imaging : JMRI · 2026Article
- Predicting response to neoadjuvant hormonal therapy and prognostic outcomes in high-risk prostate cancer using MRI-based radiomics.BMC cancer · 2026Article
- MRI-based habitat analysis for pathologic response prediction after neoadjuvant chemoradiotherapy in rectal cancer: a multicenter study.European radiology · 2026Article
- Comparison of reduced FOV diffusion-weighted imaging of rectal cancer at 5.0T ultra-high field versus 3.0T MRI: image quality and histopathological T staging.BMC medical imaging · 2025Article
- Article
- Combined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.International journal of colorectal disease · 2025Article
- Article
- Article
- Region-specific Multi-Omics Modeling for Predicting Acute Radiation-Induced Proctitis in Cervical Cancer Radiotherapy: A Retrospective Analysis.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study investigated whether magnetic resonance imaging (MRI)-based radiomics features could predict good response (GR) to neoadjuvant chemoradiotherapy (nCRT) and clinical outcome in patients with locally advanced rectal cancer (LARC). Radiomics features were extracted from the T2 weighted (T2W) and Apparent diffusion coefficient (ADC) images of 1070 LARC patients retrospectively and prospectively recruited from three hospitals. To create radiomic models for GR prediction, three classifications were utilized. The radiomic model with the best performance was integrated with important clinical MRI features to create the combined model. Finally, two clinical MRI features and ten radiomic features were chosen for GR prediction. The combined model, constructed with the tumor size, MR-detected extramural venous invasion, and radiomic signature generated by Support Vector Machine (SVM), showed promising discrimination of GR, with area under the curves of 0.799 (95% CI, 0.760-0.838), 0.797 (95% CI, 0.733-0.860), 0.754 (95% CI, 0.678-0.829), and 0.727 (95% CI, 0.641-0.813) in the training and three validation datasets, respectively. Decision curve analysis verified the clinical usefulness. Furthermore, according to Kaplan-Meier curves, patients with a high likelihood of GR as determined by the combined model had better disease-free survival than those with a low probability. This radiomics model was developed based on large-sample size, multicenter datasets, and prospective validation with high radiomics quality score, and also had clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.